Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays a new revision label, updating from v3.6.6 to v3.7.0. This appears to be a backend or UI version update and does not change any study content or functionality on the page.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6, indicating a new revision of the page. This reflects maintenance rather than substantive changes to the study information.SummaryDifference0.0%

- Check22 days agoChange DetectedIPD sharing language was added, outlining access for researchers, conditions for data sharing, and how to request IPD via Vivli. It also references related privacy protections and public availability timelines.SummaryDifference0.4%

- Check36 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, indicating a minor patch to the page's metadata.SummaryDifference0.0%

- Check50 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, indicating a small platform update that does not alter the study details or displayed content.SummaryDifference0.0%

- Check65 days agoChange DetectedAdded external registry identifiers JapicCTI-194983, NMRR-19-1491-48537, jRCT2080224898, and CTR20192589 to the study record. Removed older milestone dates (2026-02-27, 2026-02-26, 2026-02, 2026-05-01) and added new dates (2026-07-13, 2026-06-17, 2026-06, 2026-12-31).SummaryDifference0.2%

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.